Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Drugs In Development, 2024 report and make more profitable business decisions.
Hereditary angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing,and difficulty breathing. Treatment includes medications such as epinephrine, antihistamines, and corticosteroids.
The Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) drugs in development market research report provide comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 30 molecules, with 30 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
ADARx Pharmaceuticals IncAstria Therapeutics Inc
Attune Pharmaceuticals
BioCryst Pharmaceuticals Inc
BioMarin Pharmaceutical Inc
Bioviz Technologies Pvt Ltd
Bridge Medicines LLC
CAMP4 Therapeutics Corp
CSL Ltd
Grit Science Biotechnology Co Ltd
Intellia Therapeutics Inc
Ionis Pharmaceuticals Inc
Kalvista Pharmaceuticals Inc
Octapharma AG
Pharming Group NV
Pharvaris NV
Ractigen Therapeutics Inc
Shanghai Argo Pharmaceutical Co Ltd
Suzhou Ribo Life Sciences Co Ltd
Takeda Pharmaceutical Co Ltd
Thea Open Innovation SASU
Verseon Corp
Yaotang (Shanghai) Biotechnology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions